*Disseminated on Behalf of Medicus Pharma Ltd.
Krypton Street Announces Medicus Pharma (NASDAQ: MDCX) Is Topping
Our Watchlist This Morning—Tuesday, August 19, 2025 And Here's Why… Limited Float: With Less Than 2.5M Shares Listed In Its Float, (MDCX) Could Have The Potential For Significant Swings If Demand Begins To Shift.
Insider Ownership: More Than 70% Of (MDCX) Shares Are Reported
As Held By Insiders.
Analyst Targets: Coverage On (MDCX) Includes Targets As High As $27, Which Suggests Over 1,200% Upside Potential From Recent Levels.
Pipeline Expansion: Pending Acquisition Positions (MDCX) To Add Teverelix For Prostate-Related Conditions. Pull Up (MDCX) This Morning While It's Still Quiet…
August 19, 2025
It's Time | See Why (NASDAQ: MDCX) is Topping Our Watchlist Today Dear Reader, Are you watching (NASDAQ: MDCX) yet? Breakthroughs in medicine often start quietly — long before they reach headlines or clinical adoption. Right now, one little-known biotech is pressing forward on two fronts that speak to areas of urgent, unmet need: prostate cancer and non-melanoma skin cancer. That company is Medicus Pharma (NASDAQ: MDCX) — and its progress is beginning to draw fresh attention from those tracking the sector, including ours. But keep in mind, (MDCX) has a very limited float, with fewer than 2.5 Mln shares listed as available to the public according to FinViz. Insider ownership is also reported at over 70%, a level that could reflect a management team's confidence in the company's direction. Recent $27 Target By Analyst Suggests Over 1,200% Upside Potential
Multiple news sites and market portals, including Benzinga, GuruFocus, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), which suggests over 1,200% upside potential from its recent $2 range. That's not the only target we're tracking. In a recently published report, Maxim Group's Jason McCarthy set a $20 target on (MDCX), which suggests over 900% upside potential from current levels. These bold projections aren't just rooted in speculation — they're tied to a pipeline that's quietly expanding with candidates designed to tackle conditions where treatment options remain limited. Among the most closely watched is a program that could reshape the treatment landscape for prostate cancer. Teverelix: A Next-Generation Candidate for Prostate Cancer
Through a pending transaction with Antev Ltd., Medicus is positioned to add Teverelix trifluoroacetate (Teverelix TFA) to its pipeline. Teverelix is a long-acting GnRH antagonist under development for high-risk prostate cancer patients and for acute urinary retention caused by enlarged prostate. What makes Teverelix different? - Rapid suppression of testosterone and prostate shrinkage
- No testosterone flare, unlike many standard therapies
- Longer dosing intervals — potentially every six weeks
- Flexible administration — both subcutaneous and intramuscular
- Potentially improved tolerability compared to existing agents like Degarelix
If ongoing studies confirm its profile, Teverelix could address the gap between injectable antagonists (frequent dosing, injection site discomfort) and daily oral therapies (compliance challenges). Future trials are expected to compare Teverelix against standard agents and assess long-term outcomes, including cardiovascular safety. SkinJect: A Novel Patch for Basal Cell Carcinoma
Medicus also controls SkinJect, a dissolvable microneedle patch designed for non-melanoma skin cancers, especially Basal Cell Carcinoma (BCC). SkinJect delivers doxorubicin directly to the lesion via microneedle arrays, aiming to eliminate tumor cells while triggering an immune response that may help prevent recurrence. Key Advantages of SkinJect
- Minimally invasive — applied in-office in under 30 minutes
- Weekly topical application over three weeks
- Interim Phase II results: >60% complete clinical response
- Potentially avoids scarring and long recovery common with Mohs surgery
- Lower projected treatment cost compared to surgery ($1,000 vs. $2,000–15,000)
With more than 5M BCC cases annually in the U.S., and standard surgical treatments often causing scarring and long recovery times, SkinJect is positioned as a promising alternative for both patients and dermatologists. Market Landscape and Growth Potential
- Prostate cancer and enlarged prostate affect countless individuals worldwide, with cardiovascular safety becoming an increasingly important factor in treatment choices.
- Skin cancer incidence continues to rise, particularly in older populations, but also increasingly among younger individuals.
- By addressing these large and growing patient populations, (MDCX)'s pipeline has the potential to expand its relevance across multiple therapeutic markets.
Why MDCX Is on the Radar
Two late-stage clinical programs, a clear strategy to expand through partnerships, and a lean market cap relative to its potential have placed MDCX on our radar. With ongoing clinical progress and expected regulatory interactions in the near term, the company stands at an important point in its development timeline. For readers tracking biotech catalysts, Medicus Pharma (NASDAQ: MDCX) is one to keep a close eye on. Medicus Pharma's Recent Developments
(MDCX) is not standing still. From high-profile deals to bold new collaborations, the company has continued to make announcements that point toward a widening pipeline and growing industry presence. Next-Gen Medicine: Medicus and HelixNano Target Cold-Chain Limitations
(MDCX) and HelixNano announced plans to collaborate on thermostable, needle-free therapeutics designed to bypass cold-chain storage and widen global availability. The partnership brings together HelixNano's mRNA platform with Medicus' microneedle delivery technology, positioning both companies at the forefront of next-generation medicine.
See full story here. Medicus Moves to Expand Pipeline Through Antev Acquisition Agreement
(MDCX) signed a definitive agreement to acquire UK-based Antev Ltd., adding Teverelix — a next-generation GnRH antagonist for prostate cancer and acute urinary retention — to its pipeline. The acquisition broadens Medicus' clinical reach and strengthens its standing in urology and oncology. See full story here. With momentum building across multiple fronts, (MDCX) is beginning to stand out from peers in the sector. And when we looked closer at the numbers, the partnerships, and the pipeline, seven distinct factors emerged that explain why this morning could be pivotal. 7 Reasons Why (NASDAQ: MDCX) Will Be Topping Our Watchlist
This Morning—Tuesday, August 19, 2025 1. Limited Float: With a small float of less than 2.5M shares available to the public, (MDCX) could witness big swing potential if demand begins to shift. 2. Insider Ownership: Over 70% insider ownership in (MDCX) reflects a leadership team deeply tied to the company's direction. 3. Analyst Targets: Recent coverage on (MDCX) targets as high as $27, which suggests over 1,200% upside potential. 4. Pipeline Expansion: Through its pending Antev acquisition, (MDCX) is positioned to add Teverelix to its portfolio for prostate-related conditions. 5. SkinJect Progress: Interim Phase II results for (MDCX)'s microneedle patch showed more than 60% complete response rates in Basal Cell Carcinoma. 6. Strategic Collaborations: (MDCX) recently joined forces with HelixNano to develop thermostable, needle-free therapeutics targeting cold-chain limitations. 7. Market Scope: By addressing both prostate cancer and skin cancer, (MDCX) is advancing programs with direct ties to large and growing patient populations. Taken together, these seven factors paint a clear picture of why (MDCX) is stepping into focus right now. And with several potential catalysts stacking across its pipeline, this morning could prove to be a key moment to keep this name on the radar. Pull Up (MDCX) This Morning While It's Still Quiet…
(MDCX) continues to build momentum across multiple programs, from advancing a skin cancer patch with promising Phase II results to securing a definitive agreement that adds a late-stage prostate therapy candidate. With a limited float and expanding partnerships, the company has positioned itself in areas of significant medical need where progress can draw attention quickly. We have all eyes on (MDCX) right now. Take a look at (MDCX) while it's still quiet. Keep an eye out for my next update—it could be hitting any moment. Sincerely, Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter | 
No comments:
Post a Comment